According to brain experts, cannabis has shown considerable promise for treating the cause of dementia and Alzheimer's, but federal regulators keep blocking their path toward a cure. "It's a totally unexplored area, because researchers have been stopped by the DEA, due to the way the agency classifies marijuana," Schubert told CNBC. "The pharmaceutical companies want to stop the use of cannabis in the research community because it's a natural product, so it can't be patented," he said. According to Schubert, that's because pharmaceutical companies are not just trying to prevent cannabis cures, but also on the wrong track for finding their own. "They are trying to use antibodies to get rid of plaque that is outside the cell, but that is too late in the disease," Schubert said.

Source: Forbes March 16, 2017 16:00 UTC